Fosfestrol


Concise Prescribing Info
Indications/Uses
Malignant neoplasms of the prostate.
Dosage/Direction for Use
Adult : PO As fosfestrol Na: 360-480 mg tid. Maintenance: 120-240 mg tid; may reduce to 240 mg/day. IV As fosfestrol Na: Initial: 600-1,200 mg/day for 5-10 days then 300 mg/day for 10-20 days. Maintenance: 300-600 mg, reduce over few mth from 4 times wkly to once wkly dosing.
Dosage Details
Intravenous
Malignant neoplasms of the prostate
Adult: As fosfestrol Na: Initially, 600-1,200 mg daily by slow inj over 1 hr to be given for 5-10 days followed by 300 mg daily for 10-20 days. Maintenance: 300-600 mg, reduce gradually over few mth from 4 times wkly to once wkly dosing.

Oral
Malignant neoplasms of the prostate
Adult: As fosfestrol Na: 360-480 mg tid. Maintenance: 120-240 mg tid; may gradually reduce to 240 mg daily.
Special Precautions
Patient w/ history of heart disease. Hepatic impairment. Pregnancy and lactation.
Adverse Reactions
Temporary burning sensation in the perineal region, pain at the site of bony metastases, fluid retention, nausea, arterial and venous thrombosis, breast enlargement in male, impotence, withdrawal bleeding, increased blood Ca level.
Action
Description: Fosfestrol inhibits the action of androgen on prostate gland and also hormone induced growth of cancer cells by competitively binding to the androgen receptors, forming a drug-receptor complex.
Storage
Store at room temp.
ATC Classification
L02AA04 - fosfestrol ; Belongs to the class of estrogens.
References
Buckingham R (ed). Fosfestrol . Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 18/04/2016.

Disclaimer: This information is independently developed by MIMS based on Fosfestrol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in